Skip to main content
Boston Scientific8-K: Capex increase

Boston Scientific invests $1.5B in MiRus LLC with a $3.0B option to acquire its TAVR business.

What happened

This major investment and potential acquisition signals a strategic push into the transcatheter aortic valve replacement (TAVR) market.

Source

SEC EDGARMay 18, 2026

Current report (Form 8-K)

Boston Scientific 8-K

Filing excerpt

On May 15, 2026, the Company acquired, for a cash payment of $1.5 billion (exclusive of a $100 million payment previously made by the Company to MiRus) (a) non-voting common equity interests constituting 33.75% of the fully diluted equity interests of MiRus and (b) an exclusive option (the “Call Option”) to acquire...all the equity interests of a wholly owned subsidiary of MiRus...for additional aggregate cash payments totaling $3.0 billion

sec.gov/Archives/edgar/data/885725/000088572526000041/bsx-20260518.htmRead the full source

Other signals in this filing (3)

Extracted by Autobound

From the Signal API record
Signal
8-K: Capex increase

What this signalsFilings often name leadership changes, deals and spending plans.

Form
8-K
Fiscal year end
05/18
Filed
May 18, 2026

The full record

From the Signal API record

Numbers

Dollar figure
$1.5B (Initial cash payment for equity in MiRus LLC and an acquisition option. An additional $3.0 billion is possible upon option exercise.)
Percent
33.75% (Acquired non-voting common equity interests of MiRus.)

Details

CIK
885725
Accession number
0000885725-26-000041
Timeframe
Immediate
Filing year
2026
Why it matters
Budget available
Signal category
Financial

Topics and mentions

Technologies

  • TAVR System

Vendors

  • MiRus LLC

Regions named

  • United States

Extraction

Confidence
High
Relevance
90%
Sentiment
Positive
Detected
May 19, 2026
signal_type
sec-8k
signal_subtype
capexIncrease

Use this data

Get every 8-K signal for Boston Scientific and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Boston Scientific this week?”

  2. Send it to your own tools

    The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/605a5aaa-0648-468c-b7a9-7bc25dbcfe50 returns this record as JSON. POST /v1/companies/enrich returns every signal for bostonscientific.com.

{
  "signal_id": "605a5aaa-0648-468c-b7a9-7bc25dbcfe50",
  "signal_type": "sec-8k",
  "signal_subtype": "capexIncrease",
  "detected_at": "2026-05-19T10:14:18.331+00:00",
  "company": {
    "name": "Boston Scientific",
    "domain": "bostonscientific.com"
  },
  "data": {
    "detail": "This major investment and potential acquisition signals a strategic push into the transcatheter aortic valve replacement (TAVR) market. Integrating MiRus's TAVR system and managing new clinical trials will require significant resources, creating opportunities for vendors in clinical trial management, R&D data platforms, and post-merger integration services.",
    "metrics": {
      "pct": 0.3375,
      "timeframe": "immediate",
      "pct_context": "Acquired non-voting common equity interests of MiRus.",
      "dollar_context": "Initial cash payment for equity in MiRus LLC and an acquisition option. An additional $3.0 billion is possible upon option exercise.",
      "dollar_millions": 1500
    },
    "summary": "Boston Scientific invests $1.5B in MiRus LLC with a $3.0B option to acquire its TAVR business.",
    "excerpts": "On May 15, 2026, the Company acquired, for a cash payment of $1.5 billion (exclusive of a $100 million payment previously made by the Company to MiRus) (a) non-voting common equity interests constituting 33.75% of the fully diluted equity interests of MiRus and (b) an exclusive option (the “Call Option”) to acquire...all the equity interests of a wholly owned subsidiary of MiRus...for additional aggregate cash payments totaling $3.0 billion",
    "relevance": 0.9,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/885725/000088572526000041/bsx-20260518.htm",
    "filing_date": "2026-05-18",
    "filing_year": 2026,
    "fiscal_year_end": "05/18",
    "sales_relevance": "Budget available",
    "signal_category": "financial",
    "regions_mentioned": [
      "United States"
    ],
    "vendors_mentioned": [
      "MiRus LLC"
    ],
    "technologies_mentioned": [
      "TAVR System"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.